HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics
NRx Pharmaceuticals (NASDAQ:NRXP) announced that its subsidiary, HOPE Therapeutics, has signed a binding Letter of Intent to acquire a 49% interest in Cohen and Associates, a premier interventional psychiatry clinic in western Florida.
Cohen and Associates, founded by Dr. Rebecca Cohen, will serve as a foundational clinic in the Sarasota-Bradenton region. The clinic specializes in treating suicidal depression, PTSD, and other CNS disorders through various treatments including ketamine, Spravato, and Transcranial Magnetic Stimulation (TMS). The acquisition is expected to be immediately accretive to revenue and EBITDA.
NRx Pharmaceuticals (NASDAQ:NRXP) ha annunciato che la sua controllata, HOPE Therapeutics, ha firmato una Lettera di Intenti vincolante per acquisire una quota del 49% in Cohen and Associates, una clinica di psichiatria interventistica di rilievo nella Florida occidentale.
Cohen and Associates, fondata dalla Dott.ssa Rebecca Cohen, sarà una clinica pilastro nella regione di Sarasota-Bradenton. La clinica è specializzata nel trattamento della depressione suicidaria, del disturbo da stress post-traumatico (PTSD) e di altri disturbi del sistema nervoso centrale tramite diverse terapie, tra cui ketamina, Spravato e Stimolazione Magnetica Transcranica (TMS). L’acquisizione dovrebbe apportare un contributo immediato ai ricavi e all’EBITDA.
NRx Pharmaceuticals (NASDAQ:NRXP) anunció que su subsidiaria, HOPE Therapeutics, ha firmado una Carta de Intención vinculante para adquirir un 49% de participación en Cohen and Associates, una clínica líder en psiquiatría intervencionista en el oeste de Florida.
Cohen and Associates, fundada por la Dra. Rebecca Cohen, servirá como una clínica fundamental en la región de Sarasota-Bradenton. La clínica se especializa en el tratamiento de depresión suicida, TEPT y otros trastornos del sistema nervioso central mediante diversos tratamientos, incluyendo ketamina, Spravato y Estimulación Magnética Transcraneal (TMS). Se espera que la adquisición contribuya de inmediato a los ingresos y al EBITDA.
NRx Pharmaceuticals (NASDAQ:NRXP)는 자회사인 HOPE Therapeutics가 플로리다 서부의 주요 개입 정신과 클리닉인 Cohen and Associates의 49% 지분을 인수하기 위한 구속력 있는 의향서를 체결했다고 발표했습니다.
Cohen and Associates는 Rebecca Cohen 박사가 설립했으며 Sarasota-Bradenton 지역의 핵심 클리닉 역할을 할 예정입니다. 이 클리닉은 자살 우울증, PTSD 및 기타 중추신경계 질환을 케타민, Spravato, 경두개 자기자극(TMS) 등 다양한 치료법으로 전문적으로 치료합니다. 이번 인수는 즉시 매출과 EBITDA에 긍정적인 영향을 미칠 것으로 예상됩니다.
NRx Pharmaceuticals (NASDAQ:NRXP) a annoncé que sa filiale, HOPE Therapeutics, a signé une lettre d'intention contraignante pour acquérir une participation de 49% dans Cohen and Associates, une clinique de psychiatrie interventionnelle de premier plan dans l'ouest de la Floride.
Cohen and Associates, fondée par la Dr Rebecca Cohen, servira de clinique de référence dans la région de Sarasota-Bradenton. La clinique est spécialisée dans le traitement de la dépression suicidaire, du trouble de stress post-traumatique (TSPT) et d'autres troubles du système nerveux central grâce à divers traitements, notamment la kétamine, Spravato et la stimulation magnétique transcrânienne (SMT). L'acquisition devrait contribuer immédiatement au chiffre d'affaires et à l'EBITDA.
NRx Pharmaceuticals (NASDAQ:NRXP) gab bekannt, dass seine Tochtergesellschaft HOPE Therapeutics eine verbindliche Absichtserklärung zum Erwerb eines 49% Anteils an Cohen and Associates, einer führenden interventionellen Psychiatrieklinik in Westflorida, unterzeichnet hat.
Cohen and Associates, gegründet von Dr. Rebecca Cohen, wird als Grundpfeiler-Klinik in der Region Sarasota-Bradenton dienen. Die Klinik ist auf die Behandlung von suizidaler Depression, PTBS und anderen ZNS-Erkrankungen spezialisiert und bietet verschiedene Therapien an, darunter Ketamin, Spravato und transkranielle Magnetstimulation (TMS). Die Akquisition wird voraussichtlich sofort umsatz- und EBITDA-steigernd wirken.
- Acquisition expected to be immediately accretive to revenue and EBITDA
- Expands HOPE's presence into the strategic Sarasota-Bradenton market
- Adds established clinic with comprehensive treatment offerings including ketamine, Spravato, and TMS
- Brings expertise of nationally recognized TMS expert Dr. Rebecca Cohen
- Only acquiring minority stake (49%) in the clinic
- Transaction still subject to definitive agreement and closing conditions
Insights
NRXP's subsidiary acquiring a 49% stake in Cohen's psychiatry clinic enhances revenue and footprint in Florida's mental healthcare market.
NRx Pharmaceuticals is strategically expanding its healthcare delivery footprint through its HOPE Therapeutics subsidiary with a binding LOI to acquire a 49% interest in Cohen and Associates, a respected neuropsychiatry clinic in western Florida. This move represents a calculated vertical integration strategy, combining NRx's pharmaceutical development with direct clinical service delivery.
The financial implications appear positive as the acquisition is explicitly described as "immediately accretive to revenue and EBITDA" - a key positive indicator for investors. Cohen's established practice (founded in 2014) brings diverse treatment capabilities including ketamine therapy, Spravato, Transcranial Magnetic Stimulation, and medication management for conditions like suicidal depression and PTSD.
This acquisition aligns with the growing trend of pharmaceutical companies establishing direct patient care channels. For NRx, this potentially creates multiple benefits: 1) direct revenue from clinical services, 2) real-world data collection opportunities for their pharmaceutical development pipeline, and 3) established distribution channels for future approved therapies in the mental health space.
The Florida location is noteworthy given the state's large retirement population and corresponding mental health needs. By establishing Cohen as a "foundational clinic" in the Sarasota-Bradenton area, NRXP appears to be pursuing a hub-and-spoke expansion model in demographically favorable regions. The retention of Dr. Cohen, with her credentials from Tufts, Boston University, and Georgetown, provides continuity of leadership and clinical expertise during this transition.
- Cohen and Associates is a highly respected neuropsychiatry clinic in western
Florida - Cohen to serve as foundational clinic in the
Sarasota -Bradenton area ofFlorida - Acquisition expected to be immediately accretive to revenue and EBITDA
Cohen is one of the premier Interventional Psychiatry clinics in the region. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, Transcranial Magnetic Stimulation ("TMS") as well as medication management.
Dr. Cohen is an Interventional Psychiatrist and Psychopharmacologist specializing in the treatment of mood and anxiety disorders as well as a nationally recognized expert in TMS. Her practice was established in 2014 to deliver top tier Psychiatric evaluations and comprehensive clinical care. She has expanded the scope of her practice with the addition of outstanding colleagues and technologies to deliver the most evidence-based and compassionate care in the region. Dr. Cohen's academic background spans Tufts University,
"We are delighted to welcome Rebecca and her team to the HOPE family. Her extensive experience with neuroplastic therapies, combined with compassionate patient care exemplify our culture of bringing HOPE to life," said Jonathan Javitt, MD MPH and Matthew Duffy, Co-CEOs of HOPE Therapeutics.
"I am thrilled to be working with HOPE at this exciting juncture in the company's evolution. Our goal will always be to deliver outstanding patient care by offering the best available treatments and individualized care," stated Dr. Cohen.
The potential acquisition of Cohen is subject to the execution of definitive transaction documents and standard closing requirements. Further details regarding the terms of the transaction will be disclosed at that time.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy, for suicidal treatment-resistant bipolar depression. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential as a treatment for complicated UTI.
NRx recently filed for a new Commissioner's National Priority Voucher (CNPV) for NRX-100 (preservative free IV ketamine); the CNPV is designed to facilitate approval of drugs to enhance the health interests of Americans. Additionally, NRx recently filed an Abbreviated New Drug Application (ANDA) for NRX-100 for use in ketamine's currently approved indications. Further, the Company has initiated a New Drug Application filing for NRX-100 for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality and has filed a patent for this novel formulation with the US Patent and Trademark Office.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a Healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the entry into definitive transaction documents for the acquisition of Cohen and satisfaction of closing conditions necessary to consummate the acquisition of Cohen. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements, including, without limitation, whether the Company will receive the FDA's approval for its CNPV applications for NRX-100, the Company's ability to enter into definitive transaction documents, if at all, whether the Company will be able to obtain financing adequate to consummate the transactions contemplated by the LOI as well as other previously announced planned acquisitions, and the Company's ability to integrate Cohen and other planned acquisitions in a manner that is revenue and EBITDA accretive to NRx. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information: | |
Matthew Duffy | Brian Korb |
Co-CEO, Hope Therapeutics, Inc. | Managing Partner, astr partners |
Chief Business Officer, NRx Pharmaceuticals, Inc. | (917) 653-5122 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-agreement-to-acquire-interest-in-cohen-and-associates-llc-for-hopes-network-of-interventional-psychiatry-clinics-302492190.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What percentage stake is NRXP acquiring in Cohen and Associates?
What treatments does Cohen and Associates clinic offer?
How will the Cohen acquisition affect NRXP's financials?
Where is the Cohen and Associates clinic located?
When was Cohen and Associates established?
